Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093.

Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Falanga A, Russo L, Tartari CJ.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011068.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten Cate H, Falanga A.

Blood. 2011;118(9):2599-601.

Defining the thrombotic risk in patients with myeloproliferative neoplasms.

Vianello F, Battisti A, Cella G, Marchetti M, Falanga A.

ScientificWorldJournal. 2011;11:1131-7.

All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells.

Marchetti M, Russo L, Balducci D, Falanga A.

Thromb Res. 2011;128(4):368-74.

LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.

Vignoli A, Marchetti M, Russo L, Cantalino E, Diani E, Bonacina G, Falanga A.

Cancer Invest. 2011;29(2):153-61.